Most clinical studies suggest that p53 alterations in the case of non-small cell lung carcinoma (NSCLC) carry a worse prognosis and may be relatively more resistant to chemotherapy and radiation [16], for review see [17]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.